These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 21298351

  • 1. Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery.
    Lee JM, Yang SY, Yang PW, Shun CT, Wu MT, Hsu CH, Lin CC, Cheng JC, Wang YH, Chuang TH, Chen JS, Hsu HH, Huang PM, Kuo SW, Lee YC.
    Ann Surg Oncol; 2011 Jul; 18(7):2066-73. PubMed ID: 21298351
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Interleukin-2 -330T>G genetic polymorphism associates with prognosis following surgery for thoracic esophageal squamous cell cancer.
    Motoyama S, Miura M, Hinai Y, Maruyama K, Usami S, Yoshino K, Nakatsu T, Saito H, Minamiya Y, Ogawa J.
    Ann Surg Oncol; 2011 Jul; 18(7):1995-2002. PubMed ID: 21258967
    [Abstract] [Full Text] [Related]

  • 4. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, Danenberg KD, Salonga D, Chen P, Tsao-Wei D, Groshen S, Hoelscher AH, Schneider PM, Danenberg PV.
    J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
    [Abstract] [Full Text] [Related]

  • 5. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
    Cheng JC, Graber MS, Hsu FM, Tsai CL, Castaneda L, Lee JM, Chang DT, Koong AC.
    Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
    [Abstract] [Full Text] [Related]

  • 6. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
    Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, Becker K, Langer R, Buechler M, Hemminki K, Kumar R.
    Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
    [Abstract] [Full Text] [Related]

  • 7. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R.
    Int J Radiat Oncol Biol Phys; 2004 Dec 01; 60(5):1484-93. PubMed ID: 15590179
    [Abstract] [Full Text] [Related]

  • 8. Use of germline polymorphisms in predicting concurrent chemoradiotherapy response in esophageal cancer.
    Chen PC, Chen YC, Lai LC, Tsai MH, Chen SK, Yang PW, Lee YC, Hsiao CK, Lee JM, Chuang EY.
    Int J Radiat Oncol Biol Phys; 2012 Apr 01; 82(5):1996-2003. PubMed ID: 21596488
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
    Makino T, Yamasaki M, Miyata H, Yoshioka S, Takiguchi S, Fujiwara Y, Nakajima K, Nishida T, Mori M, Doki Y.
    Ann Surg Oncol; 2010 Mar 01; 17(3):804-11. PubMed ID: 19885698
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
    Toiyama Y, Inoue Y, Saigusa S, Okugawa Y, Yokoe T, Tanaka K, Miki C, Kusunoki M.
    Clin Oncol (R Coll Radiol); 2010 May 01; 22(4):272-80. PubMed ID: 20117921
    [Abstract] [Full Text] [Related]

  • 14. The survival impact of XPA and XPC genetic polymorphisms on patients with esophageal squamous cell carcinoma.
    Yang PW, Hsieh CY, Kuo FT, Huang PM, Hsu HH, Kuo SW, Chen JS, Lee JM.
    Ann Surg Oncol; 2013 Feb 01; 20(2):562-71. PubMed ID: 22941172
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
    Watanabe M, Baba Y, Yoshida N, Ishimoto T, Nagai Y, Iwatsuki M, Iwagami S, Baba H.
    Ann Surg Oncol; 2014 Sep 01; 21(9):2838-44. PubMed ID: 24715216
    [Abstract] [Full Text] [Related]

  • 18. REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy.
    Motoyama S, Sugiyama T, Ueno Y, Okamoto H, Takasawa S, Nanjo H, Watanabe H, Maruyama K, Okuyama M, Ogawa J.
    Ann Surg Oncol; 2006 Dec 01; 13(12):1724-31. PubMed ID: 17009160
    [Abstract] [Full Text] [Related]

  • 19. COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma.
    Akutsu Y, Hanari N, Yusup G, Komatsu-Akimoto A, Ikeda N, Mori M, Yoneyama Y, Endo S, Miyazawa Y, Matsubara H.
    Ann Surg Oncol; 2011 Oct 01; 18(10):2946-51. PubMed ID: 21437756
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.